ATARA BIOTHERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $120.8M | $128.9M | $8.6M | $63.6M | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M | $244.7M | $216.1M |
| SG&A Expense | — | $26.3M | $39.9M | $50.9M | $71.6M | $78.8M | $64.4M | $79.6M |
| Operating Income | — | $35.9M | $-83.4M | $-276.0M | $-280.5M | $-340.5M | $-309.1M | $-295.7M |
| Operating Margin | — | 29.7% | -64.7% | -3,219.5% | -441.2% | — | — | — |
| Interest Expense | — | $3.8M | $4.6M | $5.3M | $373.0K | — | — | — |
| Pretax Income | — | $32.7M | $-85.4M | $-276.1M | $-228.3M | $-340.1M | $-306.6M | $-291.0M |
| Income Tax Expense | — | $31.0K | $-12.0K | $15.0K | $12.0K | $46.0K | $15.0K | $12.0K |
| Net Income | — | $32.7M | $-85.4M | $-276.1M | $-228.3M | $-340.1M | $-306.6M | $-291.0M |
| Net Margin | — | 27.1% | -66.2% | -3,220.9% | -359.1% | — | — | — |
| EPS (Basic) | — | $2.61 | $-11.41 | $-65.19 | $-2.24 | $-3.63 | $-4.15 | $-5.67 |
| EPS (Diluted) | — | $2.57 | $-11.41 | $-65.19 | $-2.24 | $-3.63 | $-4.15 | $-5.67 |
| Shares Outstanding (Basic) | 8.2M | 12.5M | 7.5M | 4.2M | 102.0M | 93.7M | 74.0M | 56.8M |
| Shares Outstanding (Diluted) | 8.2M | 12.7M | 7.5M | 4.2M | 102.0M | 93.7M | 74.0M | 56.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |